Table: Sumitomo Pharma -2025/26 parent results
May 13 (Reuters)-
Sumitomo Pharma Co., Ltd.
PARENT-ONLY FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
Year ended Year ended Year to NEXT
Mar 31, 2026 Mar 31, 2025 Mar 31, 2027 YEAR
LATEST YEAR-AGO COMPANY COMPANY
RESULTS RESULTS FORECAST H1 FORECAST
Sales 249.53 136.41
(+82.9 pct) (+38.9 pct)
Operating 19.36 11.60
(+66.8 pct)
Recurring 62.94 12.03
(+423.3 pct)
Net 114.98 106.19
(+8.3 pct)
EPS 289.41 yen 267.28 yen
Ann Div NIL NIL
-Q2 Div NIL NIL
-Q4 Div NIL NIL
NOTE - Sumitomo Pharma Co., Ltd..
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4506.T
Recent news on Sumitomo Pharma
See all newsSumitomo Pharma America Announces First Patient Receives Treatment In Phase 1/2A Study For Investigational Therapy Dsp-3077 For Retinitis Pigmentosa
Regarding A Report Concerning Sumitomo Pharma ( Company's Views On Gcr August 7 Report)
Brief: Sumitomo Pharma - Gotham City Research's August 3 Report Contains Numerous Statements That Are Clearly Inconsistent With Facts
Brief: Gotham City Research Holds Short Positions In Sumitomo Chemical And Sumitomo Pharmaceutical
Table: Sumitomo Pharma -Q1 group results (IFRS)